05:14 PM EST, 02/20/2025 (MT Newswires) -- Travere Therapeutics ( TVTX ) reported a Q4 non-GAAP diluted loss Thursday of $0.47 per share, narrowing from a loss of $0.94 a year earlier.

Analysts polled by FactSet expected a loss of $0.39.

Revenue for the quarter ended Dec. 31 was $74.8 million, up from $45.1 million a year earlier.

Analysts surveyed by FactSet expected $73.1 million.